Drugmaker Asks FDA To Rescind Rare Disease Status, Perks For COVID-19 Drug
By renouncing the special status, Gilead Sciences lets go of tax breaks, fee waivers and 7 years without generic competition for remdesivir, its experimental coronavirus treatment.
Read more on NPR
Health & Science - March 26, 2020 at 02:48AM - Drugmaker Asks FDA To Rescind Rare Disease Status, Perks For COVID-19 Drug
Không có nhận xét nào:
Đăng nhận xét